The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
@stevenmerrett, thanks for the reminder. Brain is not what it used to be, maybe I should not be driving this car.
@hypermarlin
July 10 is the General meeting day
http://www.omegadiagnostics.com/Portals/0/259103%20Project%20Stirling%20Web.pdf
Thats when everything gets questioned and hopefully approved etc..
Do you think that those buying blocks of £135k at 20% above the offer price share Stevens concerns? There will be a churn of placing shares, further RNS and this will be over £1 by the end of July
Steven, sorry I must have missed something. What's the significance of July 10th please?
Agreed, people getting ahead of themselves (Again) hence why lots of people have an entry point of over 60p and p!s$ed off when news is questioned on a forum. (thats the whole point of a forum)
Its worrying that this is the 2nd time news has leaked on Twitter prior to the RNS, maybe down to the timezone, however the placing shouldn't have leaked - I hope the company isn't fined for this.
Going forward once we know the take up of the OO, and we can actually sell the product into India and the RTW- good things should come here.
I wonder if the India news was released as the OO hasnt had a good take up - I presume I will now
We will know much more after July 10.
WRONG ftsedow, I'm both lol.
MIKEODX
NO one capable of reading ,thinking and understanding should think the RNS came across as having won a contract in India.
The RNS clearly stated what is it and what they expect. For anyone who has the ability to read but lacks the ability to think/understand please see below. Emphasis are in CAP.
100% worded from the RNS (Not paraphrased)
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Approval for sale REMAINS CONDITIONAL on the SUBMISSION of SUPPORTING technical data and the Company is CONFIDENT that this submission will be SUCCESSFUL, and that Omega WILL BE ABLE to SELL its ELISA antibody test DIRECTLY into this potentially SIGNIFICANT target market. The laboratory-based ELISA antibody test has HIGH QUALITY performance data and HAS BEEN INDEPENDENTLY VALIDATED by the Liverpool School of Tropical Medicine and St George's, University of London.
If you don't read this carefully, you would think that Omega are saying that they HAVE won the contract in India. It's always wise to read things carefully. Anyway, it looks like investors don't care about the latest RNS as the SP has not budged. They are probably waiting for more positive news like contract has been won in India.
But as I said before this is a step in the right direction and it's only a matter of time before real orders start coming in.
Approval for sale REMAINS CONDITIONAL on the SUBMISSION of SUPPORTING technical data and the Company is CONFIDENT that this submission will be SUCCESSFUL, and that Omega WILL BE ABLE to SELL its ELISA antibody test DIRECTLY into this potentially SIGNIFICANT target market. The laboratory-based ELISA antibody test has HIGH QUALITY performance data and HAS BEEN INDEPENDENTLY VALIDATED by the Liverpool School of Tropical Medicine and St George's, University of London.
You don't need to even 'read carefully'. That makes it sound like the company are being sly, but they're being (and always have been) very clear about what they are saying. Just because people on these boards are impatient and panicking doesn't mean anything, the company are clear and honest and are doing what they said they would do. My advice is get away from these boards and don't read the utter crap most people post for a couple of months and you'll likely be quite happy.
I've learnt from past experiences with Omega Diagnostics to read properly there announcements. This is good news but if you read carefully they haven't won any contracts with India yet. The Mologic antibody test has been approved by the CDSCO but no contracts yet. Still positive news
Thu, 2nd Jul 2020 07:08
RNS Number : 8295R
Omega Diagnostics Group PLC
02 July 2020
Approval for sale in India
Approval for sale remains conditional on the submission of supporting technical data and the Company is confident that this submission will be successful, and that Omega will be able to sell its ELISA antibody test directly into this potentially significant target market. The laboratory-based ELISA antibody test has high quality performance data and has been independently validated by the Liverpool School of Tropical Medicine and St George's, University of London.